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Abstract Cell cycle arrest after different types of DNA damage
can occur in either G1 phase or G2 phase of the cell cycle,
involving the distinct mechanisms of p53/p21Cip1=Waf1 induction,
and phosphorylation of Cdc2, respectively. Treatment of
asynchronously growing Swiss3T3 cells with the chemothera-
peutic drug adriamycin induced a predominantly G2 cell cycle
arrest. Here we investigate why Swiss3T3 cells were arrested in
G2 phase and not in G1 phase after adriamycin-induced damage.
We show that adriamycin was capable of inducing a G1 cell cycle
arrest, both during the G0-G1 transition and during the G1 phase
of the normal cell cycle. In G0 cells, adriamycin induced a
prolonged cell cycle arrest. However, adriamycin caused only a
transient cell cycle delay when added to cells at later time points
during G0-G1 transition or at the G1 phase of normal cell cycle.
The G1 arrest correlated with the induction of p53 and
p21Cip1=Waf1, and the exit from the arrest correlated with the
decline of their expression. In contrast to the G1 arrest,
adriamycin-induced G2 arrest was relatively tight and correlated
with the Thr-14/Tyr-15 phosphorylation of cyclin B-Cdc2
complexes. The relative stringency of the G1 versus G2 cell
cycle arrest may explain the predominance of G2 arrest after
adriamycin treatment in mammalian cells.
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1. Introduction
Cyclins and cyclin-dependent kinases (CDKs) are key reg-
ulators of the eukaryotic cell cycle. Cyclin B is associated with
Cdc2 and the cyclin B-Cdc2 complexes regulate entry into M
phase [1]. The cyclin A-Cdk2 and cyclin E-Cdk2 complexes
control progression through S phase and the G1-S transition
respectively [2,3]. D-type cyclins are associated with Cdk4 and
Cdk6 and the complexes are required for G1 progression [2].
The kinase activity of CDK is tightly regulated by an in-
tricate system of phosphorylation and protein-protein interac-
tion [4]. By de¢nition, the activation of CDKs is dependent on
the association with a cyclin subunit. CDKs are also regulated
by phosphorylation: the activity of CDK holoenzyme is in-
creased by phosphorylation of Thr-161 and inhibited by phos-
phorylation of Thr-14/Tyr-15. Thr-161 can be phosphorylated
by CDK-activating kinase (CAK) [5], and dephosphorylated
by the phosphatase KAP [6]. Thr-14/Tyr-15 can be phos-
phorylated by the Wee1 and Myt1, and dephosphorylated
by members of the Cdc25 phosphatase family [5]. The activity
of CDKs can be inhibited by binding to CDK inhibitors,
which include the p21 family (p21Cip1=Waf1, p27Kip1, and
p57Kip2) and the p16INK4A family (p16INK4A, p15INK4B,
p18INK4C, p19INK4D) [7].
Proper control of cell cycle progression requires several
checkpoint controls, which regulate the activities of di¡erent
CDKs to ensure that each stage of the cell cycle is completed
before the next stage is initiated [8]. Deregulation of these
checkpoint controls may allow cell cycle progression to be-
come insensitive to external signals and DNA damage [9].
Following DNA damage, two strategies are generally
adopted by cells to ensure that mutations are not passed on
to the daughter cells. On the one hand, the cell cycle can be
arrested transiently to allow time for DNA repair or be per-
manently arrested and enter a senescent state [10]. On the
other hand, the cells with damaged DNA can be eliminated
by apoptosis [11]. After DNA damage, the cell cycle can be
arrested in either G1 phase or G2 phase [12]. Both cell cycle
arrest and apoptosis after DNA damage involve p53 [13]. The
level of p53 is negatively regulated by binding to MDM2,
which targets p53 for proteasome-dependent degradation
[14]. Phosphorylation of Ser-15 and Ser-37 on p53 by ATM
or similar kinases after DNA damage inhibits the binding of
MDM2 to p53, hence increase the level and activity of p53
[15].
Once activated, p53 induces the expression of the CDK
inhibitor p21Cip1=Waf1, which in turn may be responsible for
the cell cycle arrest. Embryonic ¢broblasts derived from
p213=3 mice are impaired in their ability to arrest in G1
following DNA damage by ionizing irradiation [16,17]. In
normal human ¢broblasts, p21Cip1=Waf1 is su⁄cient for the
inhibition of cyclin A/E-Cdk2, and partly responsible for the
inhibition of cyclin D-Cdk4 after DNA damage, but is not
responsible for the inhibition of cyclin A/B-Cdc2 [18,19]. In-
stead of binding to p21Cip1=Waf1, the mitotic cyclin A/B-Cdc2
complexes are likely to be inhibited by phosphorylation on
Thr-14/Tyr-15 after DNA damage [20]. Upon DNA damage,
the protein kinase Chk1 is activated and in turn phosphory-
lates the Ser-216 residue of Cdc25C. Phosphorylation of
Cdc25C Ser-216 allows the protein 14-3-3 to bind to
Cdc25C and inactivates its phosphatase activity [21^23].
We have been interested in the mechanisms of how di¡erent
cyclin-CDK complexes that drive di¡erent parts of the cell
cycle are turned o¡ after DNA damage [19,20,24,25]. Given
that cyclin-CDK complexes that control both G1 phase and
G2 phase are turned o¡ after DNA damage, one important
question is why some DNA damaging agents arrest cells pre-
dominantly in G1 phase, while other agents arrested cells
predominantly in G2 phase. When adriamycin was added to
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asynchronously growing cells, most of the cells became ar-
rested in G2 phase. Here we investigate the basis of G1 versus
G2 cell cycle arrest after adriamycin-induced damage in
mouse ¢broblasts.
2. Materials and methods
2.1. Cell culture
Murine Swiss3T3 ¢broblasts were obtained from the American
Type Culture Collection (Rockville, MD, USA). Cells were grown
in Dulbecco’s modi¢ed Eagle’s medium (DMEM) supplemented
with 10% v/v fetal bovine serum (FBS) in a humidi¢ed incubator
with 10% CO2 at 37‡C. Adriamycin (also called doxorubicin) (Cal-
biochem, La Jolla, USA) was added at 0.2 Wg/ml ¢nal to the medium.
Cell-free extracts were prepared as described [24]. For immunoblot-
ting analysis, the cell extracts were adjusted to 1 mg/ml in SDS-sample
bu¡er and 10 Wg was loaded onto SDS-PAGE. Flow cytometry anal-
ysis was as described [25].
2.2. Cell synchronization
For serum starvation synchronization, Swiss3T3 cells were grown in
DMEM supplemented with 10% v/v FBS until the cultures reached
about 50% con£uence. The medium was then changed to DMEM
with 0.2% v/v FBS for 48 h. Cells were released from the G0 arrest
by supplying the cells with DMEM containing 10% v/v FBS. For
double thymidine synchronization, cells were incubated in medium
containing 2 mM thymidine for 16 h. The cells were released from
the ¢rst block by removing the thymidine-containing medium, washed
twice with phosphate-bu¡ered saline (PBS) (170 mM NaCl, 3 mM
KCl, 10 mM Na2HPO4, 2 mM KH2PO4), and incubated in medium
containing 24 WM deoxycytidine. After 9 h, 2 mM of thymidine was
added to the medium to block the cells a second time. After 16 h, the
cells were released from the second block as above. For serum star-
vation followed by a single thymidine block, cells were ¢rst arrested at
G0 by serum starvation as described above, and were blocked in
S phase by incubating in DMEM containing 10% v/v FBS and
2 mM thymidine for 24 h. The cells were then released by removing
the thymidine-containing medium, washed twice with PBS, and incu-
bated in medium containing 24 WM deoxycytidine. For mitotic block
synchronization, cells were arrested at G2/M by incubating in medium
containing 0.1 Wg/ml nocodazole for 16 h. To harvest the M phase-
arrested cells, the medium was removed and 10 ml of PBS was added
to the plate followed by vortexing for 2 min. The cells in the bu¡er
and in the medium were collected by centrifugation, washed with PBS,
and replated in fresh medium. Experiments described in this study
have been repeated at least twice.
2.3. Protein kinase assays
Protein kinase assays using 1 Wg of histone H1 or 2 Wg of GST-Rb
(containing the Rb pocket only) as substrates were performed as de-
scribed [19].
2.4. Antibodies and immunological methods
Anti-cyclin A monoclonal antibody E23 [24], anti-cyclin D1 poly-
clonal antibodies [19], anti-Cdc2 monoclonal antibody A17 [26], and
rat monoclonal antibodies YL1/2 against mammalian tubulin [27]
were as previously described. Rabbit anti-cyclin E antibodies were
gifts from M. Ohtsubo (Kurume University, Japan). Rabbit anti-cy-
clin B1 polyclonal antibodies were gifts from K. Yamashita (Kanaza-
wa University, Japan). Anti-p53 monoclonal antibody 421 was from
T. Hunt (Imperial Cancer Research Fund, UK). Anti-cyclin B1 mono-
clonal antibodies GNS1 (sc-245) and polyclonal antibodies raised
against the C-terminal peptide of p21Cip1=Waf1 (sc-397) were from San-
ta Cruz Biotechnology. Immunoprecipitation and immunoblotting
were performed as previously described [19].
Fig. 1. Induction of cell cycle arrest by adriamycin during G0-G1 transition. Swiss3T3 cells were arrested at G0 by serum starvation as de-
scribed in Section 2. The cells were released into the cell cycle by growing in medium containing 10% fetal bovine serum. Di¡erent sets of cells
were either (A) untreated, or treated with adriamycin at (B) 0 h; (C) 6 h; (D) 9 h; (E) 12 h; (F) 15 h after released from serum starvation.
The cells were harvested for £ow cytometry analysis at the indicated time points. The arrows indicate the time of adriamycin addition.
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3. Results
3.1. Adriamycin induces a G2/M arrest in Swiss3T3 cells,
but can cause a G1 arrest during G0-G1
We used the mouse Swiss3T3 cells to study the DNA dam-
age checkpoints because these cells display a p53/p21Cip1=Waf1
response following DNA damage, and can be arrested in G0
by serum starvation or contact inhibition [20,24,25]. Treat-
ment of asynchronously growing Swiss3T3 cells with the che-
motherapeutic drug adriamycin (also called doxorubicin) in-
duced a G2/M cell cycle arrest [25]. The majority of the
Swiss3T3 cells were arrested at G2/M phase 48 h after treat-
ment with adriamycin. The main issue that we sought to ad-
dress in this study was why Swiss3T3 cells arrested in G2/M
phase and not in G1 phase after adriamycin-induced damage.
We ¢rst investigated whether adriamycin is capable of caus-
ing a G1 cell cycle arrest in Swiss3T3 cells by treating cells
with adriamycin during the G0-G1 progression. Cells were
arrested in the quiescent G0 state by serum starvation, and
the cells were released synchronously into the cell cycle by
incubating in medium containing serum. Adriamycin was
added to the medium at di¡erent times after release from
serum starvation, and the position of the cell cycle was esti-
mated by £ow cytometry. Fig. 1A shows that after addition of
serum, the cells moved progressively through S phase (be-
tween 15^18 h), G2/M phase (around 21 h), G1 phase, and
again into the next S phase (around 30 h). In contrast, when
adriamycin was added at the time of G0 release (Fig. 1B), the
cells were arrested with a G0/G1 DNA content and did not
enter the cell cycle. The G0/G1 cell cycle arrest was observed
when cells were treated with adriamycin 6 h into the cell cycle
from G0 release (Fig. 1C). However, when the cells were
treated with adriamycin at later times (9 h and 12 h), the cells
did enter S phase, albeit much delayed in comparison to un-
treated cells (Fig. 1D and E). When adriamycin was added at
15 h after release from serum starvation (about 1^3 h before
the normal S phase), the cells did not arrest in G1 phase, but
Fig. 2. Cyclin expression and cell cycle arrest in serum starved cells.
(A) Swiss3T3 cells were arrested at G0 by serum starvation, and
were released into the cell cycle by growing in medium containing
10% fetal bovine serum. The cells were harvested at the indicated
time points and cell-free extracts were prepared. Cyclin D1, cyclin
E, cyclin A, and cyclin B1 in the cell extracts were detected by im-
munoblotting as indicated. (B) DNA damage induced a prolong cell
cycle arrest in G0 cells. Swiss3T3 cells were arrested at G0 by serum
starvation. The cells were released synchronously into the cell cycle
by incubating in medium containing 10% fetal bovine serum. At the
time of release, the cells were treated with adriamycin and harvested
after 24 h, 30 h, 48 h, and 70 h for £ow cytometry analysis. Cells
that were released into the cell cycle but without adriamycin were
harvested at 70 h as controls. The positions of the 2C and 4C
DNA contents are indicated.
Fig. 3. Cell cycle arrest induced by adriamycin treatment in G1
phase. Swiss3T3 cells were released synchronously from G2/M phase
by mitotic shake o¡ as described in Section 2. Adriamycin was
added 1 h after the cells were released. At the indicated time points
after mitotic shake o¡, cells were harvested for (A) £ow cytometry
analysis and (B) cell extracts preparation. The cell extracts were dis-
solved in SDS-sample bu¡er, applied onto SDS-PAGE (lanes 1^11:
untreated; lanes 12^21: adriamycin-treated), and subjected to immu-
noblotting with antibodies against p53 (top panel), p21Cip1=Waf1
(middle panel), or tubulin (bottom panel).
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continued the cell cycle to arrest in G2/M phase (Fig. 1F). The
time when adriamycin could induce a G0/G1 cell cycle arrest
was between the time when cyclin D1 and cyclin A were ex-
pressed, and similar to that of cyclin E (Fig. 2A).
Taken together, these data indicate that unlike in growing
cells, cells in the G0-G1 transition can be arrested in G0/G1
with adriamycin. However, the G0/G1 arrest was only e¡ec-
tive when adriamycin was added within 9 h from serum star-
vation release. Adriamycin treatment later in the cell cycle
caused only a delay in the entry into S phase or a normal S
phase entry but a G2/M cell cycle arrest. Hence the window of
time that adriamycin-induced damage can result in G0/G1 cell
cycle arrest was from G0 up to about 3 h from S phase, which
roughly corresponded to the time of cyclin E expression and
the restriction point (see Section 4).
3.2. Adriamycin induces a prolonged cell cycle arrest in G0
We next investigated whether the cell cycle arrest caused by
adriamycin during G0-G1 described above was a transient cell
cycle delay, or represented a longer term arrest. Serum starved
cells were treated with serum and adriamycin, and harvested
at time points for up to 3 days for analysis. Fig. 2B shows
that the adriamycin-treated cells remained in a G0/G1 cell
cycle arrest state for up to 70 h. Hence the arrest caused by
adriamycin in quiescent cells probably represented a long-
term cell cycle arrest.
Fig. 4. Adriamycin induces a transient cell cycle arrest in G1 phase. Swiss3T3 cells were released from serum starvation and treated with adria-
mycin at 9 h after addition of serum. At the indicated time points after release, cells were harvested for (A) £ow cytometry analysis and
(B) cell extract preparation. Cell extracts were applied onto SDS-PAGE (lanes 1^2: untreated; lanes 3^5: adriamycin-treated), and subjected to
immunoblotting with antibodies against p21Cip1=Waf1 (upper panel) or tubulin (lower panel). (C) Cell extracts (200 Wg each) were immunoprecipi-
tated with antibodies against cyclin B1 (top panel), cyclin A (middle panel), or cyclin D1 (bottom panel). The kinase activities against histone
H1 (for cyclin B1 and cyclin A) and GST-Rb (for cyclin D1) were assayed. (D) Swiss3T3 cells were released synchronously into the cell cycle
from serum starvation, and treated with adriamycin exactly as in panel (A), except that the cells were treated at 12 h after addition of serum.
Cell cycle distribution was analyzed by £ow cytometry. (E) Cell extracts were prepared from cells described in panel (D), applied onto SDS-
PAGE (lanes 1^4: untreated; lanes 5^7: adriamycin-treated), and subjected to immunoblotting with antibodies against p53 (top panel),
p21Cip1=Waf1 (middle panel), or tubulin (bottom panel).
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3.3. Adriamycin induces a transient cell cycle arrest in G1
phase, which correlates with the induction of p53 and
p21Cip1=Waf1
Given that adriamycin can cause a G1 cell cycle arrest or
delay when added to cells released from serum starvation, we
next asked whether adriamycin could also cause a G1 phase
arrest or delay during the normal cell cycle. Swiss3T3 cells
were synchronously released into G1 phase by mitotic shake
o¡. After the cells were attached to the plate, either bu¡er or
adriamycin was added to the medium. Fig. 3A shows that in
the absence of adriamycin, the majority of the cells entered
G1 phase promptly after release from mitotic shake o¡ and
moved progressively through the cell cycle and into the next
G1 phase. In contrast, the cells were arrested in G1 phase
when adriamycin was added. Signi¢cantly, however, the cells
slowly entered S phase at the later time points (12 and 15 h).
To con¢rm that p53 and p21Cip1=Waf1 were induced following
adriamycin treatment, cell extracts were prepared from cells
harvested at di¡erent time points, and were subjected to im-
munoblotting with the respective antibodies. Fig. 3B shows
that both p53 and p21Cip1=Waf1 were induced shortly after cells
in G1 phase were treated with adriamycin, but not in the
untreated cells. As a control, similar levels of tubulin were
detected irrespective of the presence or absence of adriamycin.
These results indicate that like the G0-G1 transition, the nor-
mal cell cycle can also be delayed by adriamycin treatment.
We next investigated the adriamycin-induced G1 arrest over
longer period of time (up to 72 h). Swiss3T3 cells released
from serum starvation were treated with adriamycin at either
9 h or 12 h (Fig. 4). Similar to above, adriamycin caused a G1
cell cycle arrest. But at later time points, a signi¢cant propor-
tion of cells re-entered S phase and G2 phase. This was more
marked in cells treated with adriamycin at the later time (12 h)
than the earlier time (9 h). Fig. 4 shows that p21Cip1=Waf1 was
induced in adriamycin-treated cells. The level of p21Cip1=Waf1
remained elevated during the course of the experiment when
adriamycin was added at 9 h after release from starvation.
Interestingly, p21Cip1=Waf1 was also induced when adriamycin
was added at 12 h, but then decreased at later time points.
Hence the activation of p53/p21Cip1=Waf1 after adriamycin
treatment correlated well with the G1 cell cycle arrest, and
the decrease in p53/p21Cip1=Waf1 at later time points may cor-
relate with the re-entry into S phase and G2 phase. To look at
the kinase activities associated with the cyclin-CDK com-
plexes, cyclins were immunoprecipitated from cell extracts
and the kinase activities towards histone H1 (for cyclin B
and cyclin A) or GST-Rb (for cyclin D1) were measured
(Fig. 4C). In untreated cells, the kinase activities associated
with the cyclins were relatively low at 9 h (early G1 phase),
and increased at 72 h (loss of synchrony). In contrast, the
kinase activities associated with all the cyclins remained low
after adriamycin treatment. Collectively, these results show
that adriamycin can induce a G1 arrest when added to
Swiss3T3 cells in G1 phase, but the G1 arrest is transient,
and the cells start to enter S phase and G2 phase from about
48 h.
3.4. Adriamycin induces a relatively tight cell cycle arrest in G2
phase, which correlates with the phosphorylation of Cdc2
To obtain Swiss3T3 cells in G2 phase, cells were released
synchronously from early S phase by double thymidine block.
At 4 h after release, adriamycin was added and the cells were
harvested for £ow cytometry analysis and cell extracts prepa-
ration. Fig. 5 shows that the cells entered G2 phase promptly
after release from the block (3^6 h). However, after addition
of adriamycin, the cells were arrested in G2 phase and did not
re-enter G1 phase. Fig. 5B shows that p53 and p21Cip1=Waf1
were detected 2 h after addition of adriamycin. Intriguingly,
the level of p53 was elevated in cells treated with adriamycin
for up to 15 h, but then abruptly returned to close to back-
ground level. On the other hand, p21Cip1=Waf1 was induced
throughout the experiment.
We next investigated whether adriamycin caused a transient
Fig. 5. G2/M cell cycle arrest induced by adriamycin in G2 phase.
Swiss3T3 cells were synchronized from early S phase by double thy-
midine block as described in Section 2. The cells were incubated in
medium in the absence (lanes 1^9) or presence (lanes 10^17) of
adriamycin at 4 h after release from the second thymidine block. At
the indicated time points after the cells were released, cells were har-
vested for (A) £ow cytometry analysis and (B) cell extract prepara-
tion. The cell extracts were applied onto SDS-PAGE (lanes 1^9:
untreated; lanes 10^17: adriamycin-treated), and subjected to immu-
noblotting with antibodies against p53 (top panel), p21Cip1=Waf1
(middle panel), or tubulin (bottom panel).
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or prolonged G2/M cell cycle arrest. Fig. 6A shows that when
Swiss3T3 cells in G2 phase were treated with adriamycin, the
cells were arrested with a G2/M DNA content. Signi¢cantly,
the cells continued to arrest in G2/M and did not go into G1
phase even after 72 h. Similar to Fig. 5, both p53 and
p21Cip1=Waf1 were induced initially after adriamycin treatment,
but the level of p53 reduced at later time points (Fig. 6B). The
kinase activity associated with cyclin B1-Cdc2 (the G2/M cy-
clin-CDK) was reduced after adriamycin treatment (Fig. 6C).
Fig. 6D shows that in the absence of adriamycin, the Cdc2
that associated with cyclin B1 were in the faster migrating,
active form. However, after treatment with adriamycin, the
Cdc2 that associated with cyclin B1 were shifted to the slower
migrating, Thr-14/Tyr-15-phosphorylated inactive form.
These data suggest that in comparison to the G1 arrest, the
G2/M arrest induced by adriamycin was relatively tight. Fur-
thermore, the G2/M arrest is correlated with the inactivation
of cyclin B1-Cdc2 complex and phosphorylation of Cdc2 on
Thr-14/Tyr-15.
4. Discussion
Adriamycin is a potent anthracycline, and is one of the
most widely used clinical cancer chemotherapeutic drugs.
The cellular responses to agents like adriamycin are of key
importance to tumorigenesis and cancer chemotherapy. Ac-
tions of adriamycin including DNA damage by intercalation
and complex formation with topoisomerase II [28], or oxida-
tive e¡ects [29] have been suggested. Most of the cells become
arrested in G2 phase when adriamycin is added to asynchro-
nously growing cells. However, it is clear that p21Cip1=Waf1 is
activated and the G1 and S phase cyclin-CDK complexes are
inhibited after adriamycin treatment. Since most of the cells in
an asynchronously growing population are in G1 phase, one
would expect a predominant G1 cell cycle arrest after adria-
mycin treatment. Can the predominant G2 cell cycle arrest
caused by adriamycin be explained?
We show here that Swiss3T3 cells can be arrested in G1
phase by adriamycin, either during G0-G1 transition or dur-
ing G1 of the normal cell cycle. However, the G1 arrest was
relatively transient, and cells migrated into S phase and G2
phase after 48^72 h. In contrast, the G2 DNA damage check-
point was more permanent. Hence over a longer period, cells
that initially arrested in G1 phase may eventually accumulate
in G2 phase.
Given that p21Cip1=Waf1 was induced in G1 cells after adria-
Fig. 6. Prolong G2/M cell cycle arrest induced by DNA damage in G2 cells. Swiss3T3 cells were synchronized from early S phase by serum
starvation followed by thymidine block as described in Section 2. The cells were incubated in medium in the absence or presence of adriamycin
at 4 h after release from the thymidine block. At the indicated time points, cells were harvested for (A) £ow cytometry analysis and (B) cell ex-
tract preparation. The cell extracts were applied onto SDS-PAGE (lanes 1^4: untreated; lanes 5^8: adriamycin-treated), and subjected to im-
munoblotting with antibodies against p53 (top panel), p21Cip1=Waf1 (middle panel), or tubulin (bottom panel). (C) The cell extracts (200 Wg)
were immunoprecipitated with antibodies against cyclin B1 and the histone H1 kinase activities were assayed. (D) Cell extracts (200 Wg) derived
from untreated cells harvested at 12 h (lane 1), or from cells treated with adriamycin harvested at 12 h (lane 2) and 24 h (lane 3) were immu-
noprecipitated with anti-cyclin B1 antibodies. The immunoprecipitates were applied onto 17.5% SDS-PAGE, and subjected to immunoblotting
with anti-Cdc2 antibodies. The positions of the Thr-14/Tyr-15-phosphorylated and underphosphorylated forms of Cdc2 are indicated.
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mycin treatment, why is it that the cells moved into S phase
and G2 phase after an initial delay? We show that both p53
and p21Cip1=Waf1 could be detected within several hours fol-
lowing adriamycin treatment. However, the levels of p53 and
p21Cip1=Waf1 declined over further incubation, which correlated
with the exit of G1 cell cycle arrest. This decline of p53 and
p21Cip1=Waf1 may explain the delayed exit from G1 arrest.
An interesting observation is that after G2 cells were treated
with adriamycin, p53 was induced but disappeared after 15 h
while the level of p21Cip1=Waf1 remained high. Previously we
have found that p21Cip1=Waf1 has a half-life of about 30 min
[19], hence it is unlikely that the level of p21Cip1=Waf1 can
remain elevated in the complete absence of p53. In previous
work, we have also observed that after UV-induced damage,
the induction of p21Cip1=Waf1 does not correlate with the in-
duction of p53 [19]. One possibility is that although the level
of p53 decreased after 15 h, the remaining p53 may have been
activated by other post-translational modi¢cation. Further-
more, it is possible that other p53-related proteins, like p73,
may keep the level of p21Cip1=Waf1 elevated.
When adriamycin was added to serum starved cells, the
cells entered a prolonged G0/G1 arrest; but when adriamycin
was added later during G0-G1 transition or in G1 phase, the
entry into S phase and G2 phase was merely delayed. The
window of time when the cells are prone to prolonged G0/
G1 arrest was from G0 to about the time of cyclin E induc-
tion, which is likely to correspond to the restriction point [30].
Further investigations are needed to elucidate the exact rela-
tionship between the restriction point and the ability of adria-
mycin to cause a G0/G1 cell cycle arrest. Since it takes the
cells about 18 h to get from G0 into S phase, but just 9 h from
normal G2/M into S phase, it is possible that the ability of
adriamycin to cause a G0/G1 arrest is because the cells are
exposed to adriamycin for a longer period.
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